OWP Pharmaceuticals has chosen EVERSANA to provide commercialization support for the U.S. launch of SUBVENITE® (lamotrigine) oral suspension, a recently FDA-approved treatment for epilepsy and bipolar disorders. SUBVENITE® received approval from the FDA on September 16, 2025, making it the first oral suspension form of lamotrigine authorized in the U.S. market. This formulation is designed as a ready-to-use liquid alternative for patients who struggle to swallow tablets or require individualized dosing, addressing a critical need for more flexible epilepsy therapies.
Lamotrigine is widely prescribed as an anticonvulsant and mood stabilizer, but up until now, only tablet versions were available in the United States. The new oral suspension aims to expand access for patients, especially those who prefer or require liquid medications.
EVERSANA, a life sciences commercialization company, will deploy a range of services to support SUBVENITE®’s launch, including field team deployment, data analytics, and co-pay solutions. The partnership builds on an alliance between OWP Pharmaceuticals and EVERSANA established in 2022 to advance oral liquid neuroscience treatments.
OWP, founded in 2014, also partners with the ROW Foundation to deliver humanitarian aid to epilepsy patients globally. The company states that roughly 80% of people with epilepsy live in developing countries, where three-quarters lack access to treatment. OWP’s broader goal is to make innovative therapies like SUBVENITE® accessible to underserved patient populations worldwide.